Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Ther · 2019 · PMC6778570 · PMID 31292928

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

just failed to reach significancep = 0.06so close (0.05 < p ≤ 0.1)

In contrast, lixisenatide (ELIXA study) had a neutral effect on CV outcomes [ 44 ], whereas the EXSCEL study assessing the once-weekly exenatide preparation just failed to reach significance for CV benefit with a 9% reduction in events (CI 0.83–1.00; p = 0.06) although a significant reduction in cardiovascular mortality was observed (Table 3 ) [ 45 ].

also in 279 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.